Estatísticas para COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
Total de visitas
| views | |
|---|---|
| COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network | 23 |
Total de visitas por mês
| views | |
|---|---|
| fevereiro 2026 | 0 |
| março 2026 | 0 |
| abril 2026 | 7 |
| maio 2026 | 0 |
| junho 2026 | 1 |
| julho 2026 | 8 |
| agosto 2026 | 0 |
Downloads
| views | |
|---|---|
| Influenza Resp Viruses - 2025 - Laniece Delaunay - COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic.pdf | 41 |
Top de consultas por país
| views | |
|---|---|
| Portugal | 14 |
| Estados Unidos | 4 |
| Canadá | 2 |
| Irão | 2 |
| Reino Unido | 1 |
Top de consultas por cidade
| views | |
|---|---|
| Braga | 14 |
| Los Angeles | 1 |
| Montreal | 1 |
| New York | 1 |
| San Jose | 1 |